Literature DB >> 26574013

In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.

Naoki Kohira1, Joshua West2, Akinobu Ito3, Tsukasa Ito-Horiyama3, Rio Nakamura3, Takafumi Sato3, Stephen Rittenhouse2, Masakatsu Tsuji3, Yoshinori Yamano3.   

Abstract

S-649266 is a novel siderophore cephalosporin antibiotic with a catechol moiety on the 3-position side chain. Two sets of clinical isolate collections were used to evaluate the antimicrobial activity of S-649266 against Enterobacteriaceae. These sets included 617 global isolates collected between 2009 and 2011 and 233 β-lactamase-identified isolates, including 47 KPC-, 49 NDM-, 12 VIM-, and 8 IMP-producers. The MIC90 values of S-649266 against the first set of Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Citrobacter freundii, Enterobacter aerogenes, and Enterobacter cloacae isolates were all ≤1 μg/ml, and there were only 8 isolates (1.3%) among these 617 clinical isolates with MIC values of ≥8 μg/ml. In the second set, the MIC values of S-649266 were ≤4 μg/ml against 109 strains among 116 KPC-producing and class B (metallo) carbapenemase-producing strains. In addition, S-649266 showed MIC values of ≤2 μg/ml against each of the 13 strains that produced other types of carbapenemases such as SME, NMC, and OXA-48. The mechanisms of the decreased susceptibility of 7 class B carbapenemase-producing strains with MIC values of ≥16 μg/ml are uncertain. This is the first report to demonstrate that S-649266, a novel siderophore cephalosporin, has significant antimicrobial activity against Enterobacteriaceae, including strains that produce carbapenemases such as KPC and NDM-1.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26574013      PMCID: PMC4750680          DOI: 10.1128/AAC.01695-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Efflux-mediated multiresistance in Gram-negative bacteria.

Authors:  K Poole
Journal:  Clin Microbiol Infect       Date:  2004-01       Impact factor: 8.067

2.  Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae.

Authors:  George A Jacoby; Debra M Mills; Nancy Chow
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 3.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.

Authors:  Johann D D Pitout; Kevin B Laupland
Journal:  Lancet Infect Dis       Date:  2008-03       Impact factor: 25.071

4.  Siderophores as drug delivery agents: application of the "Trojan Horse" strategy.

Authors:  Ute Möllmann; Lothar Heinisch; Adolf Bauernfeind; Thilo Köhler; Dorothe Ankel-Fuchs
Journal:  Biometals       Date:  2009-02-12       Impact factor: 2.949

5.  Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013.

Authors:  C Glasner; B Albiger; G Buist; A Tambić Andrasević; R Canton; Y Carmeli; A W Friedrich; C G Giske; Y Glupczynski; M Gniadkowski; D M Livermore; P Nordmann; L Poirel; G M Rossolini; H Seifert; A Vatopoulos; T Walsh; N Woodford; T Donker; D L Monnet; H Grundmann
Journal:  Euro Surveill       Date:  2013-07-11

Review 6.  Antibiotics in the clinical pipeline in 2013.

Authors:  Mark S Butler; Mark A Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2013-09-04       Impact factor: 2.649

7.  Enhanced resistance to cefotaxime and imipenem associated with outer membrane protein alterations in Enterobacter aerogenes.

Authors:  J M Hopkins; K J Towner
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

8.  Clinically relevant Gram-negative resistance mechanisms have no effect on the efficacy of MC-1, a novel siderophore-conjugated monocarbam.

Authors:  Craig J McPherson; Lisa M Aschenbrenner; Brian M Lacey; Kelly C Fahnoe; Margaret M Lemmon; Steven M Finegan; Baswanth Tadakamalla; John P O'Donnell; John P Mueller; Andrew P Tomaras
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

9.  In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.

Authors:  Malcolm G P Page; Clothilde Dantier; Eric Desarbre
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

10.  Emergence of imipenem resistance in clinical Escherichia coli during therapy.

Authors:  Jesús Oteo; Alberto Delgado-Iribarren; Dolores Vega; Verónica Bautista; María Cruz Rodríguez; María Velasco; José María Saavedra; María Pérez-Vázquez; Silvia García-Cobos; Luis Martínez-Martínez; José Campos
Journal:  Int J Antimicrob Agents       Date:  2008-09-04       Impact factor: 5.283

View more
  86 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

2.  Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters.

Authors:  Takayuki Katsube; Shiro Miyazaki; Yukitoshi Narukawa; Martha Hernandez-Illas; Toshihiro Wajima
Journal:  Eur J Clin Pharmacol       Date:  2018-04-07       Impact factor: 2.953

Review 3.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

Review 4.  [New β‑lactam antibiotics and β‑lactamase inhibitors against multidrug-resistant Gram-negative bacteria].

Authors:  Alexander Mischnik; Christoph Lübbert; Nico T Mutters
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

Review 5.  Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Authors:  George G Zhanel; Alyssa R Golden; Sheryl Zelenitsky; Karyn Wiebe; Courtney K Lawrence; Heather J Adam; Temilolu Idowu; Ronald Domalaon; Frank Schweizer; Michael A Zhanel; Philippe R S Lagacé-Wiens; Andrew J Walkty; Ayman Noreddin; Joseph P Lynch Iii; James A Karlowsky
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

6.  Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases.

Authors:  Tsukasa Ito-Horiyama; Yoshikazu Ishii; Akinobu Ito; Takafumi Sato; Rio Nakamura; Norio Fukuhara; Masakatsu Tsuji; Yoshinori Yamano; Keizo Yamaguchi; Kazuhiro Tateda
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

7.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

8.  Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.

Authors:  Marguerite L Monogue; Masakatsu Tsuji; Yoshinori Yamano; Roger Echols; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 9.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

Review 10.  NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings.

Authors:  Wenjing Wu; Yu Feng; Guangmin Tang; Fu Qiao; Alan McNally; Zhiyong Zong
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.